Performance Correction. AstraZeneca and Abraxis shall discuss each report delivered pursuant to Sections 8.2 and 8.3 promptly after the delivery thereof. In the event that any such report indicates that either Party may not achieve the required performance criteria with regard to Detailing activity and sales force management for the then-current Trimester, the Parties shall use good faith efforts jointly to develop and implement corrective action to enable such Party to achieve such criteria.
Appears in 2 contracts
Sources: Co Promotion and Strategic Marketing Services Agreement, Co Promotion and Strategic Marketing Services Agreement (Abraxis BioScience, Inc.)